<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635400</url>
  </required_header>
  <id_info>
    <org_study_id>UGT1A1-01</org_study_id>
    <nct_id>NCT01635400</nct_id>
  </id_info>
  <brief_title>Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer</brief_title>
  <official_title>Phase â…¡ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the correlation between uridine diphosphate
      glucuronosyl transferase 1A1(UGT1A1) gene polymorphisms and the side effect and efficacy of
      irinotecan in patients with small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In multiple studies of metastatic colorectal cancer,uridine diphosphate glucuronosyl
      transferase 1A1(UGT1A1) gene polymorphisms and its correlation with irinotecan-associated
      side effects have been confirmed.Data from several studies indicated an improved clinical
      outcome of patients who had received an irinotecan-based regimen.In order to find out the
      correlation between UGT1A1 gene polymorphisms and the side effect and efficacy of irinotecan
      in patients with small cell lung cancer,we designed this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side effect of chemotherapy</measure>
    <time_frame>within the first 30 days (plus or minus 3 days) after chemotherapy</time_frame>
    <description>myelosuppression,diarrhea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate of chemotherapy</measure>
    <time_frame>tumor assessments after two cycles of chemotherapy,an expected average of 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Small Cell Carcinoma of Lung</condition>
  <arm_group>
    <arm_group_label>UGT1A1 wild type (6/6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UGT1A1 heterozygous genotype (6/7)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UGT1A1 homozygous genotype(7/7)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>irinotecan 180mg/m2 i.v. over 30 min d1,q2w</description>
    <arm_group_label>UGT1A1 wild type (6/6)</arm_group_label>
    <arm_group_label>UGT1A1 heterozygous genotype (6/7)</arm_group_label>
    <arm_group_label>UGT1A1 homozygous genotype(7/7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of refractory or relapsed small cell lung cancer

          -  Physical examination and routine laboratory tests show no contraindications to
             chemotherapy

        Exclusion Criteria:

          -  Pregnant and nursing women

          -  Brain metastasis with symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan Yun</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fan Yun</last_name>
    <phone>86057188122192</phone>
    <email>fanyun@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Yun</last_name>
      <phone>0086-571-88122192</phone>
      <email>fanyun@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Fan Yun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irinotecan</keyword>
  <keyword>UGT1A1 Gene Polymorphisms</keyword>
  <keyword>Small Cell Carcinoma of Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

